Polpharma Header

Polpharma Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Evotec

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Just- Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

Details:

The programme includes upstream and downstream process, analytical method, and formulation development with a view to support commercial manufacturing of ALPN 303.

Lead Product(s): ALPN-303

Therapeutic Area: Immunology Product Name: ALPN-303

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Alpine Immune Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Expanded Collaboration August 10, 2022

ASK
US

Upload
your Pipeline Activity

Grunenthal

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Grünenthal's Glucocorticoid Receptor Modulator Enters Clinical Development

Details:

Phase III studies investigating efficacy, safety and tolerability of Qutenza (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and the efficacy, safety and tolerability of Resiniferatoxin in patients with pain associated with osteoarthritis of the knee.

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 27, 2021

ASK
US

Upload
your Pipeline Activity

Merck Group

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MoonLake Immunotherapeutics Licensed Tri-Specific Nanobody® Sonelokimab from Merck KGaA

Details:

MoonLake Immunotherapeutics plans to accelerate the development of Sonelokimab in multiple inflammatory diseases in dermatology and rheumatology driven by IL-17A and IL-17F.

Lead Product(s): Sonelokimab

Therapeutic Area: Immunology Product Name: M1095

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: MoonLake Immunotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 03, 2021

ASK
US

Upload
your Pipeline Activity

TolerogenixX

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection

Details:

The so-called TOL-1 study met all endpoints and demonstrated the feasibility and safety of MIC-Lx administration in inducing donor-specific tolerance in kidney transplant recipients.

Lead Product(s): MIC-Lx

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY